Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development

(Nasdaq: VCYT), a leading genomic diagnostics company, today
announced that it has named Alfred “Freddie” Bowie, Jr., Ph.D., as vice
president, corporate and business development. In this role, Dr. Bowie
will lead the company’s strategic planning process and be responsible
for identifying, evaluating and executing technology and business
partnerships, licensing and acquisitions as well as managing
biopharmaceutical collaborations to help drive long-term profitable
growth for Veracyte.

I am thrilled to welcome Freddie to the Veracyte team,” said Bonnie
Anderson, Veracyte’s chairman and chief executive officer. “As an
accomplished executive with a strong scientific background, Freddie
brings more than 10 years of strategic corporate and business
development experience to our company. His broad skillset, which spans
corporate strategy, business planning, alliance management and business
operations, will be instrumental in helping us achieve our strategic

Prior to joining Veracyte, Dr. Bowie led strategic planning, corporate
development and competitive intelligence at Foundation Medicine, a
wholly owned subsidiary of Roche. He also served in corporate and
business development positions of increasing responsibility at Tecan
Group and Danaher Corporation. Dr. Bowie began his career in management
consulting at The Boston Consulting Group where he advised clients in
the pharmaceutical, biotechnology and life sciences tools industries.

Dr. Bowie received his B.S. in chemistry from Davidson College and holds
a Ph.D. in synthetic organic chemistry from the University of
California, Berkeley. He also completed a National Institute of Health
fellowship at Harvard Medical School’s Institute of Chemistry and
Chemical Biology.

About Veracyte

Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that
improves patient care by providing trustworthy and actionable answers to
challenging clinical questions. The company’s products uniquely combine
advanced genomic technology, clinical science and machine learning to
provide answers that give physicians and patients a clear path forward,
informing both diagnosis and treatment decisions without the need for
costly, risky surgeries that are often unnecessary. Since its founding
in 2008, Veracyte has commercialized three genomic tests, which are
transforming the diagnosis of thyroid cancer, lung cancer and idiopathic
pulmonary fibrosis. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).

Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks
of Veracyte, Inc.


Investor and Media Contact:
Angie McCabe, 650-243-6371
President, Investor Relations and Corporate Communications
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.